Novavax COVID-19 vaccine
Novavax COVID-19 vaccine (pronunciation: /ˈnoʊvəvæks koʊvɪd naɪnˈtiːn væksiːn/) is a protein subunit COVID-19 vaccine developed by Novavax, an American vaccine development company.
Etymology
The term "Novavax" is derived from the name of the company that developed the vaccine, Novavax. The term "COVID-19" is an acronym for "coronavirus disease 2019," the year the disease was first identified. The term "vaccine" comes from the Latin vaccinus, meaning "of or from the cow," referencing the early practice of using cowpox to immunize against smallpox.
Description
The Novavax COVID-19 vaccine, also known as NVX-CoV2373, is a recombinant nanoparticle protein-based vaccine. It contains the full-length, pre-fusion spike protein of the SARS-CoV-2 virus, the virus that causes COVID-19. The spike protein is produced in insect cells using baculovirus expression technology and is combined with Novavax's proprietary saponin-based Matrix-M adjuvant to enhance the immune response.
Efficacy
Clinical trials have shown that the Novavax COVID-19 vaccine is effective at preventing COVID-19. The vaccine has been found to have an efficacy rate of 89.3% in a Phase 3 trial conducted in the United Kingdom.
Administration
The Novavax COVID-19 vaccine is administered as an intramuscular injection, typically in the upper arm. The vaccine is given in two doses, 21 days apart.
Side Effects
Common side effects of the Novavax COVID-19 vaccine include pain and swelling at the injection site, fatigue, headache, muscle pain, and fever.
Related Terms
External links
- Medical encyclopedia article on Novavax COVID-19 vaccine
- Wikipedia's article - Novavax COVID-19 vaccine
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski